“......Jolly followed by asking about the Compan

“......Jolly followed by asking about the Company’s BLA (Biologics License Application). Dr. Pourhassan explained that the Company is still in the process of filing the rest of their BLA to the FDA, however, the outcome is looking positive. He explained that the Company might be able to complete their BLA by the end of August 2019 for clinical and end of September 2019 for their manufacturing, which makes achieving final approval by next year, first or second quarter very possible.

Jolly then asked about the Company’s strategy for revenue. Dr. Pourhassan explained that raising the necessary funds and receiving FDA approval for their treatments are key to having revenue. “The strategy is to make sure we stand strong at this point,” stated Dr. Pourhassan. He added that having revenue is not too far from us and will represent a significant step for our shareholders.....”